close-icon

Log In to Bolder Science

Don't have an account? Sign Up

close-icon

Please enter your email address.

You will receive a link to create a new password via email.

Log In

close-icon

Create an Account

  • 8 characters minimum
  • First character may not be a number
  • Last character may not be a number

By completing and submitting this form, you agree to allow Bolder Science to collect the information provided and to receive communications from Bolder Science in the future regarding disease education and research updates.

close-icon

Welcome and thank you for creating an account!

At Bolder Science, we want your clinical trial search experience to be the best it can be. Complete the following prompts to easily find the trials you are interested in and see trials recruiting near you. You can adjust these selections in your dashboard after creating your account.

Condition Categories

Condition categories are pulled directly from ClinicalTrials.gov. Choose 1 or more condition categories that you are interested in:

Clinical Trials of Interest

When I’m looking for information on clinical trials, I usually am interested in...

Set a default location

Filter 2,488 trials Clear all
Filter by:

Modified Ketogenic Diet and Ketamine for Anorexia Nervosa

  • Status Active, not recruiting
    Active, not recruiting
  • Condition Anorexia Nervosa
    Anorexia Nervosa
  • Phase Phase 1
    Phase 1
INTERVENTION

Drug: Ketamine Hcl 50Mg/Ml Inj

Eligibility
  • Ages: 18 to 65 Years (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
INTERVENTION

Drug: Ketamine Hcl 50Mg/Ml Inj

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Lori Calabrese MD Innovative Psychiatry, South Windsor, Connecticut, United States

Brief Summary

This Open-Label Pilot Study Aims to Determine Whether a Two-Part Sequenced Out Patient Procedure Utilizing a Modified Ketogenic Diet Followed by a Series of Titrated Ketamine Infusions Results in Improvement or Remission of Chronic Anorexia Nervosa in Adults with Symptoms of Anorexia for at Least 3 Years Despite Treatment Involving at Least 2 Different Modalities. The Hypothesis is That the Diet Addresses Core Metabolic Deficits in the "Anorexic Brain" and Primes the Response to Ketamine.

ASLAN001 in Combination With Oxaliplatin and Capecitabine or Oxaliplatin and 5-FU With Leucovorin

  • Status Active, not recruiting
    Active, not recruiting
  • Condition Solid Tumors
    Solid Tumors
  • Phase Phase 1
    Phase 1
INTERVENTION

Drug: ASLAN001+ CAPOX (Oxaliplatin, capecitabine), Drug: ASLAN001 + mFolfox6 (5-FU, leucovorin)

Eligibility
  • Ages: 21 Years and older (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
INTERVENTION

Drug: ASLAN001+ CAPOX (Oxaliplatin, capecitabine), Drug: ASLAN001 + mFolfox6 (5-FU, leucovorin)

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

National Cancer Centre, Singapore, Singapore

Brief Summary

This is a Phase I, open-label, dose escalation study of ASLAN001 given in combination with CAPOX or mFolfox6, in patients with metastatic solid tumours, whom are suitable to receive CAPOX or mFolfox6, or with tumours that have dysregulated EGFR or HER2 signaling.

A Clinical Study Evaluating the Safety and Efficacy of BinD19 Treatment in Childhood R/R ALL and Lymphoma Subjects

  • Status Active, not recruiting
    Active, not recruiting
  • Condition Relapsed B-cell Acute Lymphoblastic Leukemia, Childhood, Refracto...
    Relapsed B-cell Acute Lymphoblastic Leukemia, Childhood, Refracto...
  • Phase Phase 1 Phase 2
    Phase 1 Phase 2
INTERVENTION

Biological: BinD19

Eligibility
  • Ages: 1 to 18 Year (Child, Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
INTERVENTION

Biological: BinD19

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Children's Hospital of Fudan University, Shanghai, Shanghai, China

Brief Summary

This is a single arm, open-label, uni-center, phase I/II study to determine the safety and efficacy of an experimental therapy called BinD19 cells in childhood patients with B-cell acute lymphoblastic leukemia or lymphoma, who are chemo-refractory, relapsed after allogeneic SCT, or are otherwise ineligible for allogeneic stem cell transplant.

A Clinical Trial of CNCT19 Cells in the Treatment of CD19 Positive Relapsed or Refractory Diffuse Non-Hodgkin Lymphoma

  • Status Active, not recruiting
    Active, not recruiting
  • Condition Diffuse Non-Hodgkin Lymphoma
    Diffuse Non-Hodgkin Lymphoma
  • Phase Phase 1
    Phase 1
INTERVENTION

Biological: single dose of CNCT19

Eligibility
  • Ages: 18 to 70 Years (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
INTERVENTION

Biological: single dose of CNCT19

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Henan Cancer Hospital, Zhengzhou, Henan, China

Brief Summary

This is a single arm, open-label, non-randomized, dose-escalation, phase I study to determine the safety and efficacy of CNCT19 in adult patients with relapsed or refractory diffuse Non-Hodgkin lymphoma.

Allogeneic ABCB5-positive Limbal Stem Cells for Treatment of LSCD

  • Status Active, not recruiting
    Active, not recruiting
  • Condition Not provided
    Not provided
  • Phase Phase 1 Phase 2
    Phase 1 Phase 2
INTERVENTION

Not provided

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
INTERVENTION

Not provided

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Brief Summary

The aim of this clinical trial is to investigate the efficacy (by monitoring neovascularization and epithelial defects) of up to four doses of the investigational medicinal product (IMP) LSC2 topically administered on the target eye of patients with LSCD. Further, safety of the IMP during and after application will be investigated (by monitoring adverse events [AEs]).

Allogeneic Mesenchymal Stem Cells for Radiation-induced Hyposalivation and Xerostomia/Dry Mouth

  • Status Active, not recruiting
    Active, not recruiting
  • Condition Xerostomia Due to Radiotherapy, Hyposalivation, Xerostomia, Oroph...
    Xerostomia Due to Radiotherapy, Hyposalivation, Xerostomia, Oroph...
  • Phase Phase 1
    Phase 1
INTERVENTION

Biological: Allogeneic adipose derived stem/stromal cells

Eligibility
  • Ages: 18 to 75 Years (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: Yes
INTERVENTION

Biological: Allogeneic adipose derived stem/stromal cells

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Department of Otolaryngology, Rigshospitalet, University Hospital of Copenhagen, Copenhagen, Denmark

Brief Summary

An investigator-initiated, non-randomized, open label study to investigate the safety, feasibility and tolerability of intraglandular injection of allogeneic mesenchymal stem/stromal cells (MSCs) into the submandibular and parotid glands of the patients with radiation-induced hyposalivation and xerostomia after radiation for a oropharyngeal squamous cell carcinoma

Anlotinib Hydrochloride Combined With AP in Stage IIIB/IIIC/IV Non-squamous Non-small-cell Lung Cancer

  • Status Active, not recruiting
    Active, not recruiting
  • Condition Non-squamous Non-small-cell Lung Cancer, Anlotinib
    Non-squamous Non-small-cell Lung Cancer, Anlotinib
  • Phase Phase 1
    Phase 1
INTERVENTION

Drug: Anlotinib Hydrochloride

Eligibility
  • Ages: 18 to 70 Years (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
INTERVENTION

Drug: Anlotinib Hydrochloride

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

West China Hospital, Sichuan University, Chendu, Sichuan, China

Brief Summary

Anlotinib is a novel oral multitarget tyrosine kinase inhibitor and primary targeted to VEGFR, FGFR, PDGFR and c-Kit. The ALTER-0303 trial showed that patients with advanced non-small cell lung cancer (NSCLC) who received anlotinib as third-line or further therapy had more survival benefit. Pemetrexed plus platinum-based chemotherapy (AP) was long considered as the first line treatment in non-squamous NSCLC patients with negative driver mutation. In this dose exploration study, the primary objective is to establish the safety profile of anlotinib combined with AP in non-squamous NSCLC patients by identifying dose limiting toxicity (DLT), maximum tolerance dose (MTD), the recommended phase II dose, and schedule. Secondary objective includes the assessment of preliminary antitumor effect.

Salsalate in Patients Mild to Moderate Alzheimer's Disease

  • Status Active, not recruiting
    Active, not recruiting
  • Condition Alzheimer Disease
    Alzheimer Disease
  • Phase Phase 1
    Phase 1
INTERVENTION

Drug: Salsalate, Drug: Placebo

Eligibility
  • Ages: 50 to 85 Years (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
INTERVENTION

Drug: Salsalate, Drug: Placebo

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

University of California, San Diego, San Diego, California, United States

Brief Summary

The purpose of the study is to test the safety and tolerability of twice daily Salsalate in patients with mild to moderate Alzheimer's Disease. Half of the participants will receive Salsalate and half will receive placebo during the 1-year duration of the study.

Cellular Immunotherapy for Patients With High Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia

  • Status Active, not recruiting
    Active, not recruiting
  • Condition Myelodysplastic Syndromes, Acute Myeloid Leukemia
    Myelodysplastic Syndromes, Acute Myeloid Leukemia
  • Phase Phase 1 Phase 2
    Phase 1 Phase 2
INTERVENTION

Biological: Autologous dendritic cells electroporated with WT1 mRNA

Eligibility
  • Ages: 18 to 70 Years (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
INTERVENTION

Biological: Autologous dendritic cells electroporated with WT1 mRNA

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Hematology and Transfusion Medicine Center, Campinas, São Paulo, Brazil

Brief Summary

The main objective of this work is to conduct a clinical study for the development and application of a vaccine with autologous dendritic cells submitted to electroporation with Wilm's tumor 1 (WT1) messenger ribonucleic acid (mRNA), as an adjuvant treatment of high-risk Myelodysplastic Syndromes and Acute Myeloid Leukemia, aiming to delay the progression of the disease or its relapse and increase overall and event-free survival.

Convalescent Plasma for the Treatment of COVID-19 (Coronavirus Disease 2019)

  • Status Active, not recruiting
    Active, not recruiting
  • Condition Covid19
    Covid19
  • Phase Phase 1
    Phase 1
INTERVENTION

Biological: COVID 19 Convalescent Plasma

Eligibility
  • Ages: 18 Years and older (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
INTERVENTION

Biological: COVID 19 Convalescent Plasma

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Houston Methodist Hopsital, Houston, Texas, United States

Brief Summary

This pilot, prospective study will assess the safety and efficacy of COVID-19 convalescent plasma versus standard care as treatment for severe and/or critical COVID-19 (as defined in the inclusion criteria) in adults 18 years of age and older. A total of 350 eligible subjects will receive a transfusion of anti-SARS-CoV2 ( severe acute respiratory syndrome) convalescent plasma.